尿蛋白四联检测在糖尿病早期肾损伤中的临床应用(1)
[摘要] 目的 分析尿蛋白四联检测在糖尿病早期肾损伤中的临床应用、观察其治疗效果及有效性。方法 2017年11月—2018年12月抽取50例该院收治的糖尿病早期肾损伤患者与同一时段该院进行健康体检者50名作为研究对象，前者为观察组、后者为对照组。两组研究对象均实施尿蛋白四联检测，对比两组患者尿蛋白四联检测糖尿病早期肾损伤阳性检出率。结果 观察组四联检测水平明显高于对照组，差异有统计学意义(P<0.05)。尿蛋白四联检测糖尿病早期肾损伤阳性检出率明显高于单纯检测阳性检出率，差异有统计学意义(P<0.05)。结论 尿蛋白四联检测在糖尿病早期肾损伤中，临床应用效果显著，值得推广。
[关键词] 尿蛋白四联检测;糖尿病早期肾损伤;临床应用
[中图分类号] R587 [文献标识码] A [文章编号] 1672-4062(2019)10(b)-0054-02
[Abstract] Objective To analyze the clinical application of quadruple detection of urinary protein in early diabetic kidney injury， and to observe its therapeutic effect and effectiveness. Methods From November 2017 to December 2018 50 patients with early diabetic kidney disease admitted to the hospital and 50 healthy subjects in our hospital at the same time were selected as the study group. The former was the observation group and the latter was the control group. The urinary protein quadruple detection was performed in both groups， and the positive detection rate of early renal injury in diabetic rats was compared between the two groups. Results The detection level of the four groups in the observation group was significantly higher than that in the control group， and the difference was statistically significant(P<0.05). The positive detection rate of urinary protein quadruple detection in early diabetic kidney injury was significantly higher than that in simple detection， the difference was statistically significant(P<0.05). Conclusion The quadruple detection of urinary protein in the early stage of diabetic kidney injury， the clinical application effect is significant， it is worth promoting.
[Key words] Urine protein quadruple detection; Early diabetic kidney injury; Clinical application
糖尿病腎损伤属于临床最常见的糖尿病慢性并发症之一，其也是引起糖尿病患者死亡的主要原因之一[1]。糖尿病早期肾损伤无明显症状，病情较为隐匿，无明显的临床特征，故在诊断中，存在一定的困难。随着病情的进展，肾功能会出现进行性恶化，加重病情的同时增加患者痛苦[2]。因此，临床应积极开展糖尿病早期肾损伤诊断干预，对控制病情的进展、提高治疗效果具有重要作用。临床研究发现，尿蛋白是糖尿病早期肾损伤诊断的重要标志，在早期糖尿病肾损伤诊断中发挥着重要作用。该次研究选定2017年11月—2018年12月该院收治的50例糖尿病早期肾损伤患者开展该次研究，评价尿蛋白四联检测在糖尿病早期肾损伤中的临床应用效果观察及有效性，报道如下。
1 资料与方法
1.1 一般资料
抽取50例该院收治的糖尿病早期肾损伤患者与该院进行健康体检者50名作为研究对象，前者为观察组、后者为对照组。观察组：男性35例、女性15例;年龄40～77岁，平均年龄为(58.66±10.20)岁;病程在1～16年，平均病程为(8.22±3.05)年。对照组：男性33名、女性17名，年龄39～76岁，平均年龄为(59.05±10.11)岁。基线资料两组相比差异无统计学意义(P>0.05)，可比较。
观察组纳入标准：病情稳定者;没有生命危险者;理解与沟通能力正常者。
两组研究对象均知情，并签署同意书。该次研究医院伦理委员会已批准。
排除标准：病情危重者;精神疾病者;家属不愿参与研究者。, 百拇医药(魏兰)
[关键词] 尿蛋白四联检测;糖尿病早期肾损伤;临床应用
[中图分类号] R587 [文献标识码] A [文章编号] 1672-4062(2019)10(b)-0054-02
[Abstract] Objective To analyze the clinical application of quadruple detection of urinary protein in early diabetic kidney injury， and to observe its therapeutic effect and effectiveness. Methods From November 2017 to December 2018 50 patients with early diabetic kidney disease admitted to the hospital and 50 healthy subjects in our hospital at the same time were selected as the study group. The former was the observation group and the latter was the control group. The urinary protein quadruple detection was performed in both groups， and the positive detection rate of early renal injury in diabetic rats was compared between the two groups. Results The detection level of the four groups in the observation group was significantly higher than that in the control group， and the difference was statistically significant(P<0.05). The positive detection rate of urinary protein quadruple detection in early diabetic kidney injury was significantly higher than that in simple detection， the difference was statistically significant(P<0.05). Conclusion The quadruple detection of urinary protein in the early stage of diabetic kidney injury， the clinical application effect is significant， it is worth promoting.
[Key words] Urine protein quadruple detection; Early diabetic kidney injury; Clinical application
糖尿病腎损伤属于临床最常见的糖尿病慢性并发症之一，其也是引起糖尿病患者死亡的主要原因之一[1]。糖尿病早期肾损伤无明显症状，病情较为隐匿，无明显的临床特征，故在诊断中，存在一定的困难。随着病情的进展，肾功能会出现进行性恶化，加重病情的同时增加患者痛苦[2]。因此，临床应积极开展糖尿病早期肾损伤诊断干预，对控制病情的进展、提高治疗效果具有重要作用。临床研究发现，尿蛋白是糖尿病早期肾损伤诊断的重要标志，在早期糖尿病肾损伤诊断中发挥着重要作用。该次研究选定2017年11月—2018年12月该院收治的50例糖尿病早期肾损伤患者开展该次研究，评价尿蛋白四联检测在糖尿病早期肾损伤中的临床应用效果观察及有效性，报道如下。
1 资料与方法
1.1 一般资料
抽取50例该院收治的糖尿病早期肾损伤患者与该院进行健康体检者50名作为研究对象，前者为观察组、后者为对照组。观察组：男性35例、女性15例;年龄40～77岁，平均年龄为(58.66±10.20)岁;病程在1～16年，平均病程为(8.22±3.05)年。对照组：男性33名、女性17名，年龄39～76岁，平均年龄为(59.05±10.11)岁。基线资料两组相比差异无统计学意义(P>0.05)，可比较。
观察组纳入标准：病情稳定者;没有生命危险者;理解与沟通能力正常者。
两组研究对象均知情，并签署同意书。该次研究医院伦理委员会已批准。
排除标准：病情危重者;精神疾病者;家属不愿参与研究者。, 百拇医药(魏兰)